CN115531347B - Astaxanthin nano-particle based on tea polyphenol mediation and preparation method thereof - Google Patents

Astaxanthin nano-particle based on tea polyphenol mediation and preparation method thereof Download PDF

Info

Publication number
CN115531347B
CN115531347B CN202211333584.5A CN202211333584A CN115531347B CN 115531347 B CN115531347 B CN 115531347B CN 202211333584 A CN202211333584 A CN 202211333584A CN 115531347 B CN115531347 B CN 115531347B
Authority
CN
China
Prior art keywords
astaxanthin
solution
nano
tea polyphenol
mediation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202211333584.5A
Other languages
Chinese (zh)
Other versions
CN115531347A (en
Inventor
宋玉昆
谭明乾
张秀敏
张彩芳
周婧琦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dalian Polytechnic University
Original Assignee
Dalian Polytechnic University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalian Polytechnic University filed Critical Dalian Polytechnic University
Priority to CN202211333584.5A priority Critical patent/CN115531347B/en
Publication of CN115531347A publication Critical patent/CN115531347A/en
Application granted granted Critical
Publication of CN115531347B publication Critical patent/CN115531347B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/045—Organic compounds containing nitrogen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The application discloses astaxanthin nano-particles based on tea polyphenol mediation and a preparation method thereof, belonging to the technical field of crossing of food science and biomedical application. The preparation method of the astaxanthin nano-particles based on the mediation of tea polyphenol comprises the steps of dissolving tea polyphenol and food additives containing aldehyde groups in an aqueous solution, and magnetically stirring to form a mixed solution; adding an astaxanthin solution into the mixed solution; then adding sea cucumber peptide, and performing magnetic stirring to trigger reaction; and after the reaction is finished, centrifuging, washing and drying to obtain the catalyst. The astaxanthin nano-particles prepared by the method have good biocompatibility and inhibition and alleviation effects on cell oxidative stress injury caused by hydrogen peroxide, can obviously improve injury denaturation of enteritis tissues, and have very good application prospects in the industries of medicines and health-care products.

Description

Astaxanthin nano-particle based on tea polyphenol mediation and preparation method thereof
Technical Field
The application relates to astaxanthin nano-particles based on tea polyphenol mediation and a preparation method thereof, belonging to the technical field of crossing of food science and biomedical application.
Background
With the increasing living standard, the requirements of people on edible foods are greatly increased, the requirements of 'eating satiety' are changed into eating nutrition and health, the foods are more favored by the biological active ingredients except for the main functions of providing nutrition energy for human bodies, and the functional factors in the foods mainly comprise amino acids, polypeptides, proteins, functional lipids, polysaccharides, oligosaccharides, terpenes, polyphenols, carotenoid, flavonoids, probiotics, minerals, vitamins and the like, and the functional factors play an important role in improving the quality of the foods, regulating the physiological functions of organisms, preventing diseases and regulating the health of human bodies. However, many food functional factors have the defects of poor solubility, poor stability, low bioavailability and the like, are easily influenced by factors such as temperature, oxygen, pH value, illumination, humidity, enzyme, metal ions and the like, and can not be widely applied due to bottleneck in processing industrialization.
Plant polyphenol is a rich natural substance, and has wide application in the fields of disease treatment, environmental protection, energy resources, tissue engineering, cosmetics, health care and the like. Green tea polyphenols are representative edible polyphenols with antioxidant and anti-inflammatory activities, mainly comprising (-) -epigallocatechin-3-gallate (EGCG), (-) -epigallocatechin-3-gallate (ECG) and (-) -Epicatechin (EC), EGCG being the most active components in tea polyphenols, having good amphiphilicity, being capable of interacting with hydrophilic and hydrophobic small molecular substances, and crosslinking properties, and being commonly used in the preparation of carrier systems.
In order to overcome the low solubility, stability and bioavailability of the functional factors, a carrier such as nano particles, liposome, microcapsule, vesicle, emulsion and the like is designed, and the utilization rate of the functional factors is improved. In recent years, nanomaterials have received considerable attention for their potential functional platform in cosmetics, nutritional supplements, disease prevention, drug delivery, etc., which provides a powerful means as an encapsulation carrier system for substances. The preparation of an ideal nanoparticle carrier should have good biocompatibility, controlled release, targeting characteristics and synergistic function with functional factors. However, most nano-carriers are not involved in the exertion of the efficacy of the functional factors, and targeted delivery of the functional factors cannot be realized.
Disclosure of Invention
[ technical problem ]
In the prior art, the nano-carrier does not participate in the exertion of the efficacy of the functional factors, and the targeting delivery of the functional factors cannot be realized.
Technical scheme
Aiming at the technical problems, the application provides the astaxanthin nano-particles based on the mediation of tea polyphenol and the preparation method thereof, wherein the astaxanthin nano-particles take natural plant polyphenol as a main raw material, and fat-soluble astaxanthin is embedded by a solvent replacement method, so that the prepared carrying system can promote the bioavailability of functional factors and has good effect of relieving the enteritis.
According to the application, tea polyphenol oligomer derivatives can be generated through the mediated participation of tea polyphenol in a Mannich reaction, wherein intermolecular hydrogen bonds and pi-pi superimposed forces increase intermolecular entanglement and interaction of the derivatives, and finally the oligomers are self-assembled into polyphenol nano-particles; the tea polyphenol nano-particle carrier prepared by applying the Mannich reaction principle is convenient and quick to synthesize, can be prepared in large quantity, is prepared from natural substances in foods, plays a role in playing a role together with the loaded functional factors, and has very good application prospect.
The application aims to provide a preparation method of astaxanthin nano-particles based on tea polyphenol mediation, which comprises the following steps:
s1, dissolving tea polyphenol and food additives containing aldehyde groups in an aqueous solution, and stirring to form a mixed solution;
s2, adding the astaxanthin solution into the mixed solution in the step S1, and then adding the peptide solution to perform magnetic stirring triggering reaction; centrifuging, washing and drying after the reaction is finished to obtain astaxanthin nano-particles; the peptide solution comprises one or more of sea cucumber peptide solution, oyster peptide solution, ginseng peptide solution and fish peptide solution.
In one embodiment, the food additive containing aldehyde groups in step S1 is vanillin or perillaldehyde.
In one embodiment, the mass concentration of tea polyphenols in the mixed solution of step S1 is 100-300ug/mL; the mass concentration of the food additive containing aldehyde group is 50-200 mug/mL.
In one embodiment, the tea polyphenols comprise one or more of (-) -epigallocatechin-3-gallate (EGCG), (-) -epigallocatechin-3-gallate and (-) -epicatechin; EGCG is preferred.
In one embodiment, the stirring in step S1 is at a speed of 800 to 1200rpm.
In one embodiment, the astaxanthin solution of step S2 has a concentration of 1mg/mL; the concentration of the peptide solution is 20-60mg/mL; the volume ratio of the astaxanthin solution to the peptide solution is 1-3: 40.
in one embodiment, the magnetic stirring in step S2 is performed at a rotational speed of 1000 to 1500rpm.
In one embodiment, the centrifugation conditions of step S2 are: centrifuging at 10000-15000 rpm/min for 20-30 min.
In one embodiment, the washing of step S2 is 3 washes with deionized water.
In one embodiment, the drying in step S2 is performed at-80 to-40 ℃ for 24-36 hours.
It is a second object of the present application to provide astaxanthin nanoparticles prepared by the method described above.
A third object of the present application is to provide an application of the astaxanthin nano-particles in preparing a medicine for alleviating colon injury.
A fourth object of the present application is to provide a pharmaceutical or health food comprising the above astaxanthin nanoparticles.
The application has the beneficial effects that:
(1) The preparation method of the carrier system has mild conditions, keeps the activity of the active substances, has simple operation in the preparation process, low energy consumption, environmental protection and controllable and uniform size of the prepared nano particles;
(2) The astaxanthin is coated by adopting a tea polyphenol-mediated carrier system, so that the problems of poor water solubility and poor thermal stability of the astaxanthin are remarkably improved, and the bioavailability of the astaxanthin is improved; and has good biocompatibility and obvious inhibition effect on cell oxidative stress injury caused by hydrogen peroxide.
(3) The astaxanthin nano-particles prepared by the application can effectively regulate pathological level of enteritis mice and obviously improve the condition of tissue degeneration of enteritis.
Drawings
FIG. 1 is an SEM image (100K) of astaxanthin nanoparticles according to example 1 of the present application;
FIG. 2 is a graph showing the cell viability of astaxanthin nanoparticles according to example 1 of the present application;
FIG. 3 shows the results of example 1, comparative example 1 and the comparative group for H according to the present application 2 O 2 Induced cell damage to interfere with the cell fluorescence pattern;
FIG. 4 is a graph showing colon imaging of mice obtained from different treatment groups according to the present application;
FIG. 5 is a graph showing colon length data obtained from different treatment groups according to the present application;
FIG. 6 is a graph showing changes in serum interleukin-1 beta content of mice obtained from different treatment groups according to the present application.
FIG. 7 is a graph showing changes in serum interleukin-6 content of mice obtained from different treatment groups according to the present application;
FIG. 8 is a graph of colon tissue sections of mice obtained from different treatment groups according to the present application.
Detailed Description
The application has been described in detail with respect to preferred embodiments thereof, and the scope of the application is not limited to the specific conditions and details of the following embodiments.
Sea cucumber peptides were supplied by Dalian blue peptide technology research and development Co., ltd, and natural polyphenol-gallate and vanillin were purchased from Ara Ding Shiji Co., ltd.
Example 1
A preparation method of astaxanthin nano-particles based on tea polyphenol mediation comprises the following steps:
s1, dissolving natural polyphenol-gallate EGCG and vanillin in 80mL of deionized water, and magnetically stirring at 1200rpm at room temperature to obtain a mixed solution, wherein the final concentration of EGCG in the mixed solution is 250 mug/mL, and the concentration of vanillin is 40ug/mL;
s2, under the condition of room temperature, dissolving 10mg of astaxanthin in 10mL of ethanol solution, adding the 10mg of astaxanthin into the mixed solution obtained in the step S1 according to the volume ratio of 1:20, adding 1mL of 30mg/mL of sea cucumber peptide, and magnetically stirring at 1200rpm to trigger the astaxanthin to be embedded;
s3, centrifuging the mixed solution after embedding the S2 at 10000rpm/min for 20min, removing supernatant, washing the obtained precipitate with deionized water for 2-3 times, and freeze-drying at-80 ℃ for 24h to obtain astaxanthin nano-particles; the astaxanthin nanoparticles were then resuspended in water to obtain an astaxanthin nanoparticle solution.
Comparative example 1
A preparation method of astaxanthin nano-particles based on tea polyphenol mediation comprises the following steps:
s1, dissolving natural polyphenol-gallate EGCG and vanillin in 80mL of deionized water, and magnetically stirring at 1200rpm at room temperature to obtain a mixed solution, wherein the final concentration of EGCG in the mixed solution is 250 mug/mL, and the concentration of vanillin is 40 mug/mL;
s2, under the condition of room temperature, 1mL of 30mg/mL sea cucumber peptide is added into the mixed solution obtained in the step S1, and the mixed solution is magnetically stirred at 1200rpm for reaction, so as to obtain carrier nano particles;
s3, dissolving 10mg of astaxanthin in 10mL of ethanol solution, adding the solution into the mixed solution after the reaction in the step S2 according to the volume ratio of 1:20, uniformly stirring, centrifuging at 10000rpm/min for 20min, removing the supernatant, washing the obtained precipitate with deionized water for 2-3 times, and freeze-drying at-80 ℃ for 24h to obtain astaxanthin nano-particles; the astaxanthin nanoparticles were then resuspended in water and the astaxanthin nanoparticle solution.
Performance measurement
1. The result of SEM scanning electron microscopy of the astaxanthin nano-particles prepared in the example 1 is shown in the attached figure 1, and the SEM scanning electron microscopy imaging result shows that the astaxanthin nano-particles are approximately spherical in shape, have a particle size of about 200nm and are uniform in shape.
2. Biological safety assay for astaxanthin nanoparticles
Taking the astaxanthin nanoparticle solution obtained in example 1 for cell viability experiments, specifically taking Raw264.7 cells as an example, diluting the astaxanthin nanoparticle solution prepared in example 1 to a series of astaxanthin nanoparticle solutions with a concentration of 5-25 mug/mL, inoculating the Raw264.7 cells into a 96-well plate, and the density is 1 multiplied by 10 5 Individual cells/well, cultured for 24 hours, then further cultured with astaxanthin nanoparticle solution for 24 hours; after the cultivation, 20. Mu.L of MTT (5 mg/mL) was added and the mixture was cultivated for 4 hours. Subsequently, the medium was replaced with 150. Mu.L of DMSO and shaken well for 10 minutes. Finally, absorbance of the 96-well plate at 490nm wavelength was measured using an enzyme-labeled instrument.
As shown in FIG. 2, the cell viability of astaxanthin nanoparticles treated with a series of concentrations of 5-25 μg/mL was improved compared with the blank group, indicating good biocompatibility of astaxanthin nanoparticles.
Raw264.7 cell injury intervention experiment
Raw264.7 cells were seeded in 12-well plates at a density of 1X 10 5 Cells/well and cultured for 24 hours. Then 1mL of the astaxanthin nanoparticle solution obtained in example 1 (wherein the effective content of astaxanthin in both the free astaxanthin and carrier mixed group and the astaxanthin nanoparticle group was 10. Mu.g/mL of astaxanthin) was taken and incubated with the astaxanthin nanoparticle solution prepared in comparative example 1 (free astaxanthin and carrier mixed group) and the carrier group (containing no astaxanthin) for 6 hours; after removal of the medium, the cells were combined with H 2 O 2 (400. Mu. Mol/L) for 30min. Then, the cells were incubated with 10. Mu. Mol/LDCFH-DA (EX=502 nm, EM=530 nm) at 37℃for 30min; finally, the cells were washed three times with PBS.
Detection of image pairs H using a Ti-S fluorescence inverted microscope 2 O 2 The fluorescence image of the induced cell injury intervention cells is shown in FIG. 3, H 2 O 2 The green fluorescence intensity of the induced RAW264.7 cells is obviously enhanced, which indicates that a large amount of ROS are generated in the cells; example 1 shows a strong green fluorescence compared to comparative example 1, the vector group and example 1Degree of attenuation, wherein example 1 significantly reduces H 2 O 2 The resulting intracellular ROS production. The result shows that the astaxanthin nano-particles prepared in the example 1 can remarkably eliminate the generation of active oxygen, keep cells in a normal state and have good intervention effect on oxidative damage.
4. Colon targeting performance assay
Intestinal inflammation experiments were performed using 6-7 week old BALB/c male mice, which were divided into 5 groups, namely, a blank group, a dextran sulfate group, a mixed group of free astaxanthin and carrier (comparative example 1), a carrier group and an astaxanthin nanoparticle group (example 1), and a mouse enteritis model was constructed using dextran sulfate.
The time period of the animal experiment was 21 days, and the first 14 days respectively, the mice of the free astaxanthin and carrier mixed group (comparative example 1), the carrier group and the astaxanthin nano-particle group (example 1) were perfused with 0.2mL of equivalent amounts of the corresponding samples (wherein the effective content of astaxanthin in the free astaxanthin and carrier mixed group and the astaxanthin nano-particle group is 1.5mg/kg of astaxanthin); free drinking water is carried out 14 days before the blank group and the dextran sulfate group;
the mice of each of the groups of dextran sulfate group, the mixed free astaxanthin and carrier group (comparative example 1) and the carrier group (example 1) were supplied with deionized water having a mass fraction of 4% dextran sulfate for free drinking; meanwhile, the free astaxanthin and carrier mixed group, the carrier group and the astaxanthin nano-particle group continue to irrigate the sample.
Mice were slaughtered on day 22, mouse serum was collected, and colon tissue was dissected and collected for each group of 3 parallel colon tissues, and the length distribution of the colon tissue was observed. The results are shown in FIGS. 4 and 5 and Table 1;
as can be seen from FIG. 4, the colon length of the dextran sulfate treated mice was significantly shortened to 5.41.+ -. 0.53cm, and the intestines had a blood sample of pus. The colon of the mice interfered with in example 1 was even and smooth, had no bloody stool, and had a colon length of 8.17.+ -. 0.29cm, similar to the control group (9.57.+ -. 0.21 cm). The colon lengths of mice treated with comparative example 1 and vehicle group were (6.07.+ -. 0.12) and (6.7.+ -. 0.17) cm, respectively. Example 1 significantly increased 51.29% after intervention compared to DSS group, significantly higher than 12.20% and 23.84% of comparative example 1 and vehicle group. These results demonstrate that example 1 significantly reduces colonic shortening and intestinal congestion in IBD model mice; the astaxanthin nano-particles are proved to have a certain protection effect on colon inflammation of mice.
Table 1 colon length of mice from different treatment groups
The results of the detection of interleukin 1 beta and interleukin-6 in the serum of the mice are shown in the accompanying figures 6 and 7, and the results show that the levels of inflammatory factors interleukin 1 beta and interleukin-6 in the serum of the mice treated with the astaxanthin nano-particles prepared in the example 1 are obviously reduced compared with the dextran sulfate group and are obviously lower than that of the free astaxanthin and carrier mixed group (comparative example 1); the astaxanthin nano-particles can obviously inhibit inflammatory factors to improve colonitis.
The results of the stained sections of the colon tissue organ (H & E) of the mice are shown in FIG. 8, the colon tissue structure of the control group is normal, the columnar epithelium is compact, the intestinal crypt is complete, and the mucous membrane and submucosa are clear. In contrast, dextran sulfate group mice had severely damaged colon, irregular epithelium, distorted crypt structure, and infiltration of inflammatory cells into lamina propria. After the astaxanthin prepared in comparative example 1 was mixed with the carrier, the nanoparticles and the carrier were dried, the damage of the crypt structure was reduced, the infiltration of inflammatory cells was weakened, the crypt structure of the astaxanthin nanoparticle group was restored, and the mucosa was smooth. And colon structure recovery was stronger than that of comparative example 1 and vehicle group. This result shows that the astaxanthin nanoparticle group prepared in example 1 has a significant degree of lesion alleviation in the colon.
In conclusion, the results show that the astaxanthin nano-particles constructed by the application can remarkably relieve colon inflammation of mice and improve the absorption and utilization rate of astaxanthin in intestinal tracts of the mice.

Claims (8)

1. A method for preparing astaxanthin nano-particles based on tea polyphenol mediation, which is characterized by comprising the following steps:
s1, dissolving tea polyphenol and food additives containing aldehyde groups in an aqueous solution, and stirring to form a mixed solution; the food additive containing aldehyde groups is vanillin; the tea polyphenol is gallate EGCG;
s2, adding the astaxanthin solution into the mixed solution in the step S1, and then adding the peptide solution to perform magnetic stirring triggering reaction; centrifuging, washing and drying after the reaction is finished to obtain astaxanthin nano-particles; the peptide solution is sea cucumber peptide solution.
2. The method according to claim 1, wherein the mass concentration of tea polyphenols in the mixed solution in step S1 is 100-300 μg/mL; the mass concentration of the food additive containing aldehyde group is 50-200 mug/mL.
3. The method of claim 1, wherein the concentration of astaxanthin solution in step S2 is 1mg/mL; the concentration of the peptide solution is 20-60mg/mL; the volume ratio of the astaxanthin solution to the peptide solution is 1-3:40.
4. The method according to claim 1, wherein the rotational speed of the magnetic stirring in step S2 is 1000 to 1500rpm.
5. The method according to claim 1, wherein the centrifugation conditions of step S2 are: centrifuging at 10000-15000 rpm/min for 20-30 min.
6. Astaxanthin nanoparticles prepared by the method of any one of claims 1-5.
7. Use of astaxanthin nanoparticles according to claim 6 for the preparation of a medicament for alleviating colon lesions.
8. A pharmaceutical product comprising the astaxanthin nanoparticle of claim 6.
CN202211333584.5A 2022-10-28 2022-10-28 Astaxanthin nano-particle based on tea polyphenol mediation and preparation method thereof Active CN115531347B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211333584.5A CN115531347B (en) 2022-10-28 2022-10-28 Astaxanthin nano-particle based on tea polyphenol mediation and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211333584.5A CN115531347B (en) 2022-10-28 2022-10-28 Astaxanthin nano-particle based on tea polyphenol mediation and preparation method thereof

Publications (2)

Publication Number Publication Date
CN115531347A CN115531347A (en) 2022-12-30
CN115531347B true CN115531347B (en) 2023-09-19

Family

ID=84717748

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211333584.5A Active CN115531347B (en) 2022-10-28 2022-10-28 Astaxanthin nano-particle based on tea polyphenol mediation and preparation method thereof

Country Status (1)

Country Link
CN (1) CN115531347B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112587503A (en) * 2020-12-21 2021-04-02 大连工业大学 Stimulus-response astaxanthin nanoparticle, preparation method thereof and application of nanoparticle in mitochondrial targeting and colon inflammation relieving direction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112587503A (en) * 2020-12-21 2021-04-02 大连工业大学 Stimulus-response astaxanthin nanoparticle, preparation method thereof and application of nanoparticle in mitochondrial targeting and colon inflammation relieving direction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biocompatible, bacteria-targeting resveratrol nanoparticles fabricated by Mannich molecular condensation for accelerating infected wound healing;Liwen Tang等;Journal of Materials Chemistry B;第10卷;第9280-9294页 *
Synthesis of Phosphinopeptides via the Mannich Ligation;Bonan Li等;ORGANIC LETTERS;第47卷;第1239-1248页 *

Also Published As

Publication number Publication date
CN115531347A (en) 2022-12-30

Similar Documents

Publication Publication Date Title
Samadi et al. Ameliorating quercetin constraints in cancer therapy with pH-responsive agarose-polyvinylpyrrolidone-hydroxyapatite nanocomposite encapsulated in double nanoemulsion
Zhang et al. A smart cauliflower-like carrier for astaxanthin delivery to relieve colon inflammation
Hao et al. Encapsulation of the flavonoid quercetin with chitosan-coated nano-liposomes
Li et al. The simultaneous loading of catechin and quercetin on chitosan-based nanoparticles as effective antioxidant and antibacterial agent
KR100473422B1 (en) A composition for an enteric coating of natural product containing lectin
Chen et al. ROS-scavenging biomaterials for periodontitis
CN111165769A (en) Preparation method of zein-bee pollen extract microcapsule
Chen et al. Chitosan-based selenium composites as potent Se supplements: Synthesis, beneficial health effects, and applications in food and agriculture
Manne et al. Pterocarpus marsupium Roxb. heartwood extract synthesized chitosan nanoparticles and its biomedical applications
Zhu et al. Creating burdock polysaccharide-oleanolic acid-ursolic acid nanoparticles to deliver enhanced anti-inflammatory effects: Fabrication, structural characterization and property evaluation
Jiao et al. Improvement in entrapment efficiency and in vitro digestion stability of lutein by zein nanocarriers with pepsin hydrolysis
Chen et al. Natural extracts for antibacterial applications
CN104288093B (en) Application of the nano drug transdermal preparation in tumour
Dong et al. Encapsulation of vitamin C by a double-layer zein/chitosan structure with improved stability and controlled release
Taebpour et al. Fabrication and characterization of PLGA polymeric nanoparticles containing Berberine and its cytotoxicity on breast cancer cell (MCF-7)
Ma et al. Preparation and characterization of bilayered microencapsulation for co-delivery Lactobacillus casei and polyphenols via Zein-chitosan complex coacervation
CN115531347B (en) Astaxanthin nano-particle based on tea polyphenol mediation and preparation method thereof
KR20220143266A (en) Orally cyclodextrin-curcumin encapsulated chitosan/alginate nanoparticles and use thereof in treating colitis
AU2018383334B2 (en) Anisotropic nanoparticle compositions and methods
Zhao et al. Visual foodborne nanoparticles for oral site-specific delivery of anthocyanins in the treatment of inflammatory bowel disease
CN114948880B (en) Preparation method of caffeic acid phenethyl ester nano stable slow release formulation
Albogamy et al. Preparation and characterization of dextran-zein-curcumin nanoconjugate for enhancement of curcumin bioactivity
WO2022179050A1 (en) Composition for preventing and treating alcoholic liver injury, preparation method therefor and application thereof
Alpizar-Reyes et al. Recent approaches in alginate-based carriers for delivery of therapeutics and biomedicine
Mekkawy et al. Evaluation of Different Surface Coating Agents for Selenium Nanoparticles: Enhanced Anti-Inflammatory Activity and Drug Loading Capacity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant